Insider · CIK 0001886575

Betz Stephen F.

Reports to the SEC for 1 company · SAN DIEGO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001886575

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−90.5K sh	$83.09	−$7.52M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−58.3K sh	$85.00	−$4.95M	79,650
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc.D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−79.7K sh	$85.00	−$6.77M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−47K sh	$41.21	−$1.94M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−65K sh	$48.14	−$3.13M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−87K sh	$41.49	−$3.61M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−110K sh	$65.36	−$7.19M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−77K sh	$64.98	−$5M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−15K sh	$61.81	−$927K	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−85K sh	$69.71	−$5.93M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−60K sh	$62.39	−$3.74M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−56.3K sh	$59.81	−$3.36M	0
2026-09-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Chief Scientific Officer	DDisposition to Issuer	−74.5K sh	$75.72	−$5.64M	0
2026-03-16	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−4,241 sh	$37.77	−$160K	137,101
2026-03-16	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−6,371 sh	$37.11	−$236K	141,342
2026-02-23	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Scientific Officer	AAward	+47K sh	—	—	47,000
2026-02-23	CRNXCrinetics Pharmaceuticals, Inc.A Award	Chief Scientific Officer	AAward	+30K sh	—	—	147,713
2025-12-26	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−18K sh	—	—	90,514
2025-12-26	CRNXCrinetics Pharmaceuticals, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+18K sh	$1.91	+$34.4K	117,713
2025-06-12	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−97.5K sh	$32.23	−$3.14M	99,713
2025-06-12	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−16.6K sh	—	—	58,198
2025-06-12	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−71.5K sh	—	—	108,514
2025-06-12	CRNXCrinetics Pharmaceuticals, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+16.6K sh	$9.28	+$154K	197,196
2025-06-12	CRNXCrinetics Pharmaceuticals, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+71.5K sh	$1.91	+$137K	180,551
2025-03-19	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−5,479 sh	$34.17	−$187K	108,879
2025-03-19	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−291 sh	$34.83	−$10.1K	108,588
2025-02-20	CRNXCrinetics Pharmaceuticals, Inc.A Award	Chief Scientific Officer	AAward	+43K sh	—	—	114,358
2025-02-20	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)A Award	Chief Scientific Officer	AAward	+65K sh	—	—	65,000
2024-12-16	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	−2,331 sh	—	—	180,039
2024-12-16	CRNXCrinetics Pharmaceuticals, Inc.M Exercise/Conversion	Chief Scientific Officer	MExercise/Conversion	+2,331 sh	$1.91	+$4,452.21	71,358
2024-11-20	CRNXCrinetics Pharmaceuticals, Inc.J Other	Chief Scientific Officer	JOther	+451 sh	$14.98	+$6,755.98	71,358
2024-09-10	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−1,035 sh	$51.50	−$53.3K	68,576
2024-08-26	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−3,000 sh	$53.19	−$160K	69,611
2024-08-12	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−3,000 sh	$47.68	−$143K	72,611
2024-07-25	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−3,000 sh	$53.43	−$160K	75,611
2024-07-10	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−3,000 sh	$48.55	−$146K	78,611
2024-06-25	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−3,000 sh	$45.37	−$136K	80,643
2024-06-10	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−3,000 sh	$43.86	−$132K	83,643
2024-05-28	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−3,000 sh	$47.49	−$142K	86,643
2024-05-10	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−3,000 sh	$49.43	−$148K	89,643
2024-03-18	CRNXCrinetics Pharmaceuticals, Inc.F Tax Payment	Chief Scientific Officer	FTax Payment	−3,655 sh	$38.14	−$139K	92,643
2024-03-04	CRNXCrinetics Pharmaceuticals, Inc.A Award	Chief Scientific Officer	AAward	+23K sh	—	—	96,298
2024-03-04	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+87K sh	—	—	87,000
2024-01-25	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−3,000 sh	$37.26	−$112K	73,298
2024-01-10	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−3,000 sh	$37.65	−$113K	76,298
2023-12-26	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−3,000 sh	$35.89	−$108K	79,298
2023-12-11	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−3,000 sh	$32.87	−$98.6K	82,298
2023-11-27	CRNXCrinetics Pharmaceuticals, Inc.S Sale	Chief Scientific Officer	SSale	−3,000 sh	$31.84	−$95.5K	85,298
2023-03-16	CRNXCrinetics Pharmaceuticals, Inc.F Tax Payment	Chief Scientific Officer	FTax Payment	−1,410 sh	$17.12	−$24.1K	86,879
2023-03-01	CRNXCrinetics Pharmaceuticals, Inc. · Stock Option (right to buy)A Award	Chief Scientific Officer	AAward	+110K sh	—	—	110,000

Recent filings

Accepted (ET)
Sep 14
Betz Stephen F.0001628280-26-059884
SEC(opens sec.gov)
Mar 184
Betz Stephen F.0001628280-26-019498
SEC(opens sec.gov)
Feb 254
Betz Stephen F.0001628280-26-011718
SEC(opens sec.gov)
Dec 294
Betz Stephen F.0001628280-25-059009
SEC(opens sec.gov)
Jun 164
Betz Stephen F.0000950170-25-086804
SEC(opens sec.gov)

Companies

Crinetics Pharmaceuticals, Inc.Chief Scientific OfficerCRNX

Address

C/O CRINETICS PHARMACEUTICALS, INC. 6055 LUSK BOULEVARD

SAN DIEGO, CA, 92121